This approval is claimed to be a significant milestone in the company’s continued worldwide expansion. Surgeons in China will now have access to the company’s full line of advanced surgical devices for sealing and dividing tissue during a broad range of surgical procedures. Unlike conventional products employing monopolar, bipolar or ultrasonic energy, the company’s instruments feature the its patented Tissue Welding technology, which uses direct heat and pressure to simultaneously seal and divide soft tissue reducing the risk of inadvertent collateral damage.
Wenjing Ding, Starion’s president and CEO, said: “The company’s Tissue Welding technology is unique to the Chinese market and it is changing the way that physicians perform a broad range of minimally invasive and open surgeries. Sealing and dividing tissue and blood vessels is a very critical point in any surgery and the company’s technology is giving surgeons greater confidence to perform this task. Opinion leaders from hospitals across various regions of China enjoyed the convenience and effectiveness of company’s instruments in their clinical trials.”